Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Allergan’s Good Looks May Be Too Pricey

Expected uptick in breast implants, wrinkle fillers is good news for Botox creator, but many investors think AGN still costs too much.

Medical Research Firms May See a Profit Pinch

Relationships with Big Pharma are changing the game.

Is Pfizer Move to Sell Non-Pharma Divisions Bad Medicine?

Pfizer has said it will shed its nutritional and animal health businesses to pump more money into its drug pipeline. But is the move risky?

Lilly Study Could Sink Prospects for Alzheimer’s Treatments

Eli Lilly's drug study failure raises questions about the safety of its Alzheimer's treatment, but will rival Bristol-Myers have success?

Is Big Pharma Resistant to Antibiotics?

Less profitable drugs take a backseat despite health risks